System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Filomena Longo is an expert in Hematology at Arcispedale Sant'Anna (Italy). As of October 2026, ScienceLeadR ranks Filomena Longo in the top 1% of experts worldwide for Anemia. Filomena Longo has authored 153 publications, the most recent in 2026, and is an investigator in 9 clinical trials, 3 of them ongoing. SLR score: 523 (community average: 125). How the SLR is computed.

LeadR Profile

Filomena Longo Arcispedale Sant'Anna Italy
523 ScienceLeadR Reputation 523

Unlock

Register Login
Network Map

Hematology

Subspecialties: Medical Imaging - Cardiology - Genetics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2004 - 2026
Source: PubMed

University of Turin

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 153

Citations

Citations: 3 273 1st author: 9 Last author: 9 Unique author: 0

Main journals

Blood 21
Am J Hematol 11
J Clin Med 11
Br J Haematol 9
Haematologica 8

Best Journals

Ann Oncol 2
Lancet 2
Eur Heart J 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
β-thalassemia as a progressive disease: age-related morbidity in the de-LIGHT study.
PMID 42817845 — hematology, thalassemia, morbidity		Haematologica20260
Age-Related Patterns of Organ-Specific Iron Distribution in Non-Transfusion-Dependent Thalassemia: A Multicenter MRI Study.
PMID 42795801 — phenotype, multiple chronic conditions, magnetic resonance imaging, thalassemia, iron overload, prevalence		J Clin Med20260
Pancreatic iron overload as a marker of endocrine complications in transfusion-dependent thalassaemia: A multicentre study.
PMID 42747066 — hematology, magnetic resonance imaging, iron overload		Br J Haematol20260
Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
PMID 42721980 — safety, pharmaceutical preparations, drug-related side effects and adverse reactions, therapeutics		Lancet Top journal20263
Determinants of liver stiffness assessed by transient elastography in transfusion-dependent thalassemia.
PMID 42555009 — research design, fibrosis, elasticity imaging techniques, transferases, transaminases, liver, thalassemia, infections, liver stiffness		Expert Rev Hematol20260

Clinical Studies 9

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 3
Phase 2 3
Phase 3 3

By status:

Completed 5
Active not recruiting 3
Recruiting 1

By type:

Interventional 6
Observational 3

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 0
multicentric5to9 0
multicentricup10 5

Main Topics

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Atrial Fibrillation in Beta Thalassemia
NCT05508932 — beta-thalassemia, arrhythmias, cardiac, atrial fibrillation, thalassemia, hemoglobinopathies		N/ARecruiting2022
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non Transfusion Dependent Alpha or Beta Thalassemia ( or NTDT)
NCT04770753 — safety, beta-thalassemia, alpha-thalassemia, tablets, thalassemia		Phase 3Active not recruiting2021
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion Dependent Alpha or Beta Thalassemia ( or TDT)
NCT04770779 — safety, beta-thalassemia, alpha-thalassemia, tablets, thalassemia		Phase 3Active not recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS